{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T20:03:59Z","timestamp":1782763439877,"version":"3.54.5"},"reference-count":184,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.msard.2020.102174","type":"journal-article","created":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T21:57:21Z","timestamp":1589234241000},"page":"102174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"special_numbering":"C","title":["The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8872-8711","authenticated-orcid":false,"given":"David","family":"Baker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Amor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angray S.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9293-8893","authenticated-orcid":false,"given":"Klaus","family":"Schmierer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9995-1700","authenticated-orcid":false,"given":"Gavin","family":"Giovannoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2020.102174_bib0001","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3389\/fimmu.2020.00056","article-title":"Event-Driven immunoprofiling predicts return of disease activity in alemtuzumab-treated multiple sclerosis","volume":"11","author":"Akg\u00fcn","year":"2020","journal-title":"Front Immunol."},{"key":"10.1016\/j.msard.2020.102174_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2020.03.007","article-title":"SARS-CoV-2 Vaccines: status report","author":"Amanat","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.msard.2020.102174_bib0003","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/cns.12793","article-title":"Transcriptome profiling of peripheral blood immune cell populations in multiple sclerosis patients before and during treatment with a sphingosine-1-phosphate receptor modulator","volume":"24","author":"Angerer","year":"2018","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.msard.2020.102174_bib0004","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1021\/acschemneuro.0c00122","article-title":"Evidence of the COVID-19 virus targeting the cns: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms","volume":"11","author":"Baig","year":"2020","journal-title":"ACS Chem. Neurosci"},{"key":"10.1016\/j.msard.2020.102174_bib0005","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ebiom.2017.01.042","article-title":"Memory B Cells are major targets for effective immunotherapy in relapsing multiple sclerosis","volume":"16","author":"Baker","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.msard.2020.102174_bib0006","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamaneurol.2017.0676","article-title":"Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of Alemtuzumab","volume":"74","author":"Baker","year":"2017","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1016\/j.msard.2020.102174_bib0007","doi-asserted-by":"crossref","first-page":"e360","DOI":"10.1212\/NXI.0000000000000360","article-title":"Both cladribine and alemtuzumab may effect MS via B-cell depletion","volume":"4","author":"Baker","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2020.102174_bib0008","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.msard.2017.09.028","article-title":"Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatment","volume":"18","author":"Baker","year":"2017","journal-title":"Mult. Scler. Relat. Disord"},{"key":"10.1016\/j.msard.2020.102174_bib0009","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1093\/brain\/awy239","article-title":"Learning from other autoimmunities to understand targeting of B cells to control multiple sclerosis","volume":"141","author":"Baker","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.msard.2020.102174_bib0010","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.msard.2019.02.018","article-title":"Potential mechanisms of action related to the efficacy and safety of cladribine","volume":"30","author":"Baker","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2020.102174_bib0011","article-title":"The ocrelizumab phase II extension trial suggests the potential to improve the risk:benefit balance in multiple sclerosis","author":"Baker","year":"2020","journal-title":"bioR\u03c7iv."},{"key":"10.1016\/j.msard.2020.102174_bib0012","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3389\/fimmu.2020.00124","article-title":"The irony of humanization: alemtuzumab, the first, but one of the most immunogenic, humanized monoclonal antibodies","volume":"11","author":"Baker","year":"2020","journal-title":"Front Immunol."},{"key":"10.1016\/j.msard.2020.102174_bib0013","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/ana.21363","article-title":"Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial","volume":"63","author":"Bar-Or","year":"2008","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2020.102174_bib0014","doi-asserted-by":"crossref","first-page":"44266","DOI":"10.18632\/oncotarget.17863","article-title":"Leflunomide\/teriflunomide inhibit Epstein-Barr virus (EBV)- induced lymphoproliferative disease and lytic viral replication","volume":"8","author":"Bilger","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.msard.2020.102174_bib0015","article-title":"Reinfection could not occur in SARS-CoV-2 infected rhesus macaques","author":"Bao","year":"2020","journal-title":"BioR\u03c7iv"},{"key":"10.1016\/j.msard.2020.102174_bib0016","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40263-020-00714-8","article-title":"Fingolimod and dimethyl-fumarate-derived lymphopenia is not associated with short-term treatment response and risk of infections in a real-life ms population","volume":"34","author":"Boffa","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2020.102174_bib0017","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s10875-007-9120-0","article-title":"Resetting the adaptive immune system after autologous stem cell transplantation: lessons from responses to vaccines","volume":"27","author":"Brinkman","year":"2007","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.msard.2020.102174_bib0018","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0002-9440(10)65400-4","article-title":"Pediatric AIDS-associated lymphocytic interstitial pneumonia and pulmonary arterio-occlusive disease: role of VCAM-1\/VLA-4 adhesion pathway and human herpesviruses","volume":"154","author":"Brodie","year":"1999","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.msard.2020.102174_bib0019","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000009507","article-title":"Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic","author":"Brownlee","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102174_bib0020","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1080\/14740338.2018.1483330","article-title":"Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis","volume":"17","author":"Buonomo","year":"2018","journal-title":"Expert Opin. Drug. Saf."},{"key":"10.1016\/j.msard.2020.102174_bib0021","article-title":"COVID-19 in the perioperative period of lung resection: a brief report from a single thoracic surgery department in Wuhan","author":"Cai","year":"2020","journal-title":"China J. Thorac. Oncol."},{"key":"10.1016\/j.msard.2020.102174_bib0022","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","article-title":"Lancet Neurol. 2014 Jun;13(6):545-56. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2020.102174_bib0023","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s00415-018-8830-y","article-title":"Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells","volume":"265","author":"Ceronie","year":"2018","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2020.102174_bib0024","doi-asserted-by":"crossref","first-page":"11034","DOI":"10.1128\/JVI.01505-14","article-title":"Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection","volume":"88","author":"Channappanavar","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.msard.2020.102174_bib0025","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ijid.2020.03.003","article-title":"Recurrence of positive SARS-CoV-2 RNA in COVID-19: A case report","volume":"93","author":"Chen","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.msard.2020.102174_bib0026","doi-asserted-by":"crossref","DOI":"10.1172\/JCI137244","article-title":"Clinical and immunological features of severe and moderate coronavirus disease 2019","author":"Chen","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.msard.2020.102174_bib0030","article-title":"The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly decimates human spleens and lymph nodes","author":"Chen","year":"2020","journal-title":"medR\u03c7iv"},{"key":"10.1016\/j.msard.2020.102174_bib0027","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1080\/22221751.2020.1732837","article-title":"Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity","volume":"9","author":"Chen","year":"2020","journal-title":"Emerg. Microbes Infect."},{"issue":"Mar 3","key":"10.1016\/j.msard.2020.102174_bib0028","first-page":"1","article-title":"The SARS-CoV-2 Vaccine Pipeline: an Overview","author":"Chen","year":"2020","journal-title":"Curr. Trop. Med. Rep."},{"key":"10.1016\/j.msard.2020.102174_bib0029","article-title":"The Presence of SARS-CoV-2 RNA in Feces of COVID-19 Patients","author":"Chen","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.msard.2020.102174_bib0031","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/jmv.25681","article-title":"Emerging coronaviruses: Genome structure, replication, and pathogenesis","volume":"92","author":"Chen","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.msard.2020.102174_bib0032","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa410","article-title":"Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19","author":"Chu","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.msard.2020.102174_bib0033","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/ni1542","article-title":"Follicular shuttling of marginal zone B cells facilitates antigen transport","volume":"9","author":"Cinamon","year":"2008","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.msard.2020.102174_bib0034","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s13311-019-00776-7","article-title":"Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?","volume":"17","author":"Clerico","year":"2020","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.msard.2020.102174_bib0035","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2020.102174_bib0036","unstructured":"Coles A, Lim M, Giovannoni G, et\u00a0al. ABN guidance on the use of disease-modifying therapies in multiple sclerosis in response to the threat of a coronavirus epidemic. 20202 Apr (https:\/\/cdn.ymaws.com\/www.theabn.org\/resource\/collection\/65C334C7-30FA-45DB-93AA-74B3A3A20293\/02.04.20_ABN_Guidance_on_DMTs_for_MS_and_COVID19_VERSION_4_April_2nd.pdf."},{"key":"10.1016\/j.msard.2020.102174_bib0037","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.msard.2019.01.038","article-title":"Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis","volume":"29","author":"Comi","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2020.102174_bib0038","article-title":"Characterizing lymphocyte counts and infection rates with long-term teriflunomide treatment: Pooled analysis of clinical trials","author":"Comi","year":"2019","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2020.102174_bib0039","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","article-title":"Multiple sclerosis","volume":"372","author":"Compston","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2020.102174_bib0040","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/cyto.a.24002","article-title":"Modena COVID-19 working group (moco19)#. Sars-cov-2, the virus that causes COVID-19: cytometry and the new challenge for global health","volume":"97","author":"Cossarizza","year":"2020","journal-title":"Cytometry A"},{"key":"10.1016\/j.msard.2020.102174_bib0041","doi-asserted-by":"crossref","DOI":"10.1002\/lt.25756","article-title":"Coronaviruses and immunosuppressed patients. The facts during the third epidemic","author":"D'Antiga","year":"2020","journal-title":"Liver Transpl."},{"key":"10.1016\/j.msard.2020.102174_bib0042","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/00365540410021144","article-title":"In vitro inhibition of SARS virus replication by human interferons","volume":"36","author":"Dahl","year":"2004","journal-title":"Scand. J. Infect. Dis."},{"key":"10.1016\/j.msard.2020.102174_bib0043","doi-asserted-by":"crossref","first-page":"m1375","DOI":"10.1136\/bmj.m1375","article-title":"Covid-19: four fifths of cases are asymptomatic, China figures indicate","volume":"369","author":"Day","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.msard.2020.102174_bib0044","doi-asserted-by":"crossref","unstructured":"de Assis RR, Jain A, Nakajima R, Jasinskas A, et\u00a0al. Analysis of SARS-CoV-2 Antibodies in COVID-19 convalescent plasma using a coronavirus antigen microarray. BioR\u03c7iv doi: 10.1101\/2020.04.15.043364.","DOI":"10.1101\/2020.04.15.043364"},{"key":"10.1016\/j.msard.2020.102174_bib0045","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jaut.2017.09.009","article-title":"Dimethyl fumarate influences innate and adaptive immunity in multiple sclerosis","volume":"86","author":"Diebold","year":"2018","journal-title":"J. Autoimmun."},{"issue":"5","key":"10.1016\/j.msard.2020.102174_bib0046","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000594","article-title":"Hepatitis E virus infections in patients with MS on oral disease-modifying treatment","volume":"6","author":"Diebold","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2020.102174_bib0047","article-title":"Predictors of mortality for patients with COVID-19 Pneumonia caused by SARS-CoV-2: a prospective cohort study","author":"Du","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.msard.2020.102174_bib0048","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2004168117","article-title":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients","author":"Duan","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.msard.2020.102174_bib0049","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.clinthera.2017.06.012","article-title":"Efficacy and safety of delayed-release dimethyl fumarate for relapsing-remitting multiple sclerosis in prior interferon users: an integrated analysis of define and confirm","volume":"39","author":"Fern\u00e1ndez","year":"2017","journal-title":"Clin. Ther."},{"issue":"S2","key":"10.1016\/j.msard.2020.102174_bib0050","first-page":"341","article-title":"Effects of ocrelizumab treatment in peripheral blood leukocyte subsets of primary progressive multiple sclerosis patients","volume":"25","author":"Fernandez Velasco","year":"2019","journal-title":"P686"},{"key":"10.1016\/j.msard.2020.102174_bib0051","article-title":"Phylogenetic network analysis of SARS-CoV-2 genomes","author":"Forster","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.msard.2020.102174_bib0052","article-title":"Pulmonary and cardiac pathology in COVID-19: the first autopsy series from New Orleans","author":"Fox","year":"2020","journal-title":"MedRxiv"},{"key":"10.1016\/j.msard.2020.102174_bib0053","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10072-018-3670-1","article-title":"Efficacy and safety of autologous hematopoietic stem-cell transplantation in multiple sclerosis: a systematic review and meta-analysis","volume":"40","author":"Ge","year":"2019","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.msard.2020.102174_bib0054","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1002\/art.23732","article-title":"Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I\/II randomized, blinded, placebo-controlled, dose-ranging study","volume":"58","author":"Genovese","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.msard.2020.102174_bib0055","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2020.102174_bib0056","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/1352458517727603","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study","volume":"24","author":"Giovannoni","year":"2018","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2020.102174_bib0057","article-title":"The COVID-19 pandemic and the use of MS disease-modifying therapies","author":"Giovannoni","year":"2020","journal-title":"Mult. Scler. Rel. Disord."},{"key":"10.1016\/j.msard.2020.102174_bib0058","article-title":"Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19","author":"Giovannoni","year":"2020","journal-title":"Mult Scler Rel Disord"},{"issue":"1","key":"10.1016\/j.msard.2020.102174_bib0059","doi-asserted-by":"crossref","DOI":"10.3390\/cells8010012","article-title":"Ocrelizumab Depletes CD20\u207a T Cells in Multiple Sclerosis Patients","volume":"8","author":"Gingele","year":"2018","journal-title":"Cells"},{"key":"10.1016\/j.msard.2020.102174_bib0060","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.virol.2005.06.026","article-title":"LSECtin interacts with filovirus glycoproteins and the spike protein of SARS coronavirus","volume":"340","author":"Gramberg","year":"2005","journal-title":"Virology"},{"issue":"6","key":"10.1016\/j.msard.2020.102174_bib0061","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1212\/NXI.0000000000000289","article-title":"Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis","volume":"3","author":"Gross","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2020.102174_bib0062","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1038\/s41467-017-01901-w","article-title":"Plasma cell survival in the absence of B cell memory","volume":"8","author":"Hammarlund","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.msard.2020.102174_bib0063","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/path.1570","article-title":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis","volume":"203","author":"Hamming","year":"2004","journal-title":"J. Pathol."},{"key":"10.1016\/j.msard.2020.102174_bib0064","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl. J. Med."},{"issue":"S2","key":"10.1016\/j.msard.2020.102174_bib0065","first-page":"890","article-title":"Efficacy and safety of ofatumumab versus teriflunomide in relapsing multiple sclerosis: results of the phase 3 ASCLEPIOS I and II trials. 336","volume":"25","author":"Hauser","year":"2019","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2020.102174_bib0066","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.0000000000004313","article-title":"Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy","volume":"89","author":"Havrdova","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102174_bib0067","author":"He","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.msard.2020.102174_bib0068","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","article-title":"Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study","volume":"19","author":"He","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2020.102174_bib0069","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMc2008597","article-title":"Neurologic Features in Severe SARS-CoV-2 Infection","author":"Helms","year":"2020","journal-title":"N Engl. J. Med"},{"key":"10.1016\/j.msard.2020.102174_bib0070","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3201\/eid1002.030482","article-title":"Interferon-beta 1a and SARS coronavirus replication","volume":"10","author":"Hensley","year":"2004","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.msard.2020.102174_bib0071","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40262-018-0695-9","article-title":"The clinical pharmacology of cladribine tablets for the treatment of relapsing multiple sclerosis","volume":"58","author":"Hermann","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.msard.2020.102174_bib0072","article-title":"Level of IL-6 predicts respiratory failure in hospitalized symptomatic COVID-19 patients","author":"Herold","year":"2020","journal-title":"medRxiv"},{"issue":"2","key":"10.1016\/j.msard.2020.102174_bib0073","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0228380","article-title":"Treatment effects of fingolimod in multiple sclerosis: Selective changes in peripheral blood lymphocyte subsets","volume":"15","author":"Hjorth","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.msard.2020.102174_bib0074","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.msard.2020.102174_bib0075","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4137\/JCNSD.S14049","article-title":"Efficacy and side effects of natalizumab therapy in patients with multiple sclerosis","volume":"6","author":"Hoepner","year":"2014","journal-title":"J. Cent. Nerv. Syst. Dis."},{"key":"10.1016\/j.msard.2020.102174_bib0076","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2020.03.006","article-title":"Rapid asymptomatic transmission of COVID-19 during the incubation period demonstrating strong infectivity in a cluster of youngsters aged 16-23 years outside Wuhan and characteristics of young patients with COVID-19: a prospective contact-tracing study","author":"Huang","year":"2020","journal-title":"J. Infect."},{"key":"10.1016\/j.msard.2020.102174_bib0077","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/10739680802425195","article-title":"Role of alpha4beta1 integrins in chemokine-induced monocyte arrest under conditions of shear stress","volume":"16","author":"Hyduk","year":"2009","journal-title":"Microcirculation"},{"key":"10.1016\/j.msard.2020.102174_bib0078","doi-asserted-by":"crossref","DOI":"10.1038\/s41577-020-0321-6","article-title":"The potential danger of suboptimal antibody responses in COVID-19","author":"Iwasaki","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.msard.2020.102174_bib0079","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101468","article-title":"Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity","volume":"37","author":"Juto","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2020.102174_bib0080","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1136\/jnnp-2018-319831","article-title":"Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis","volume":"90","author":"Kalincik","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"issue":"Suppl. 4","key":"10.1016\/j.msard.2020.102174_bib0081","first-page":"140","article-title":"Long-term safety and efficacy of ocrelizumab in patients with relapsing\u2013remitting multiple sclerosis: week 144 results of a Phase II, randomised, multicentre trial","volume":"18","author":"Kappos","year":"2012","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2020.102174_bib0082","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jns.2014.03.035","article-title":"Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis","volume":"341","author":"Kaufman","year":"2014","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2020.102174_bib0083","doi-asserted-by":"crossref","first-page":"721","DOI":"10.3389\/fimmu.2019.00721","article-title":"The Maintenance of Memory Plasma Cells","volume":"10","author":"Khodadadi","year":"2019","journal-title":"Front Immunol."},{"issue":"4","key":"10.1016\/j.msard.2020.102174_bib0084","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/oxfordjournals.aje.a120955","article-title":"Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine","volume":"89","author":"Kim","year":"1969","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.msard.2020.102174_bib0085","doi-asserted-by":"crossref","first-page":"377","DOI":"10.15585\/mmwr.mm6913e1","article-title":"Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility - King County, Washington, March 2020","volume":"69","author":"Kimball","year":"2020","journal-title":"MMWR Morb. Mortal Wkly. Rep."},{"key":"10.1016\/j.msard.2020.102174_bib0086","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1212\/WNL.0000000000000520","article-title":"Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity","volume":"82","author":"Kousin-Ezewu","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102174_bib0087","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1212\/WNL.0b013e3182143564","article-title":"Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS","volume":"76","author":"Kowarik","year":"2011","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.msard.2020.102174_bib0088","doi-asserted-by":"crossref","DOI":"10.3390\/cells9020482","article-title":"T Helper Cells: The Modulators of Inflammation in Multiple Sclerosis","volume":"9","author":"Kunkl","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.msard.2020.102174_bib0089","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2020.03.027","article-title":"Herd immunity - estimating the level required to halt the COVID-19 epidemics in affected countries","author":"Kwok","year":"2020","journal-title":"J. Infect."},{"key":"10.1016\/j.msard.2020.102174_bib0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmii.2020.02.012","article-title":"Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths","author":"Lai","year":"2020","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"10.1016\/j.msard.2020.102174_bib0091","doi-asserted-by":"crossref","DOI":"10.7326\/M20-0504","article-title":"The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application","author":"Lauer","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.msard.2020.102174_bib0092","unstructured":"Lemtrada\u00ae EU Summary of product characteristics. Nov 2019."},{"key":"10.1016\/j.msard.2020.102174_bib0093","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41564-020-0688-y","article-title":"Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses","volume":"5","author":"Letko","year":"2020","journal-title":"Nat. Microbiol"},{"key":"10.1016\/j.msard.2020.102174_bib0094","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.micinf.2012.10.008","article-title":"Extraordinary GU-rich single-strand RNA identified from SARS coronavirus contributes an excessive innate immune response","volume":"15","author":"Li","year":"2013","journal-title":"Microbes Infect"},{"key":"10.1016\/j.msard.2020.102174_bib0095","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/cei.13208","article-title":"Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis","volume":"194","author":"Li","year":"2018","journal-title":"Clin. Exp. Immunol"},{"key":"10.1016\/j.msard.2020.102174_bib0096","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.123158","article-title":"Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection","volume":"4","author":"Liu","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.msard.2020.102174_bib0097","article-title":"Correlation Between Relative Nasopharyngeal Virus RNA Load and Lymphocyte Count Disease Severity in Patients with COVID-19","author":"Liu","year":"2020","journal-title":"Viral Immunol"},{"key":"10.1016\/j.msard.2020.102174_bib0098","article-title":"Correlation Between Relative Nasopharyngeal Virus RNA Load and Lymphocyte Count Disease Severity in Patients with COVID-19","author":"Liu","year":"2020","journal-title":"Viral Immunol"},{"key":"10.1016\/j.msard.2020.102174_bib0099","article-title":"Lymphocyte subset (CD4+, CD8+) counts reflect the severity of infection and predict the clinical outcomes in patients with COVID-19","author":"Liu","year":"2020","journal-title":"J. Infect."},{"key":"10.1016\/j.msard.2020.102174_bib0100","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.25860","article-title":"Clinical and demographic characteristics of patients dying from COVID-19 in Italy versus China","author":"Lippi","year":"2020","journal-title":"J. Med. Virol"},{"issue":"10224","key":"10.1016\/j.msard.2020.102174_bib0101","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2020.102174_bib0102","article-title":"SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells","author":"Lukassen","year":"2020","journal-title":"EMBO J"},{"key":"10.1016\/j.msard.2020.102174_bib0103","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies","volume":"77","author":"Luna","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2020.102174_bib0104","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.25801","article-title":"Tocilizumab treatment in COVID-19: A single center experience","author":"Luo","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.msard.2020.102174_bib0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.trsl.2020.04.007","article-title":"Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases","author":"Magro","year":"2020","journal-title":"Transl. Res."},{"key":"10.1016\/j.msard.2020.102174_bib0106","unstructured":"Mavenclad\u00ae EU Summary of product characteristics. Jul 2018."},{"key":"10.1016\/j.msard.2020.102174_bib0107","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1212\/WNL.0b013e3182a35215","article-title":"Immune competence after alemtuzumab treatment of multiple sclerosis","volume":"81","author":"McCarthy","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102174_bib0108","doi-asserted-by":"crossref","first-page":"e1724","DOI":"10.1212\/WNL.0000000000007262","article-title":"Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice","volume":"92","author":"Mehta","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102174_bib0109","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"Clinical Investigators. N Engl. J. Med."},{"key":"10.1016\/j.msard.2020.102174_bib0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2020.03.062","article-title":"A first Case of Meningitis\/Encephalitis associated with SARS-Coronavirus-2","author":"Moriguchi","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.msard.2020.102174_bib0111","article-title":"Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study","author":"Naismith","year":"2019","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2020.102174_bib0112","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1001\/jamaneurol.2019.0522","article-title":"Fulminant hepatitis associated with echovirus 25 during treatment with ocrelizumab for multiple sclerosis","volume":"76","author":"Nicolini","year":"2019","journal-title":"JAMA Neurol."},{"issue":"S2","key":"10.1016\/j.msard.2020.102174_bib0113","first-page":"509","article-title":"Tailoring B-cells depleting therapy in MS according to memory B-cells monitoring: a pilot study. P971","volume":"25","author":"Novi","year":"2019","journal-title":"Mult Scler."},{"key":"10.1016\/j.msard.2020.102174_bib0114","article-title":"Weak induction of interferon expression by sars-cov-2 supports clinical trials of interferon lambda to treat early COVID-19","author":"O'Brien","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.msard.2020.102174_bib0115","doi-asserted-by":"crossref","unstructured":"Okba NMA, M\u00fcller MA, Li W, et\u00a0al. Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease 2019 patients. Emerg Infect Dis.2020;26(7). doi: 10.3201\/eid2607.200841. [Epub].","DOI":"10.3201\/eid2607.200841"},{"key":"10.1016\/j.msard.2020.102174_bib0116","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/ene.13537","article-title":"Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory","volume":"25","author":"Olberg","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2020.102174_bib0117","unstructured":"Ocrevus\u00ae EU Summary Product Characterisitics, Sep 2018."},{"key":"10.1016\/j.msard.2020.102174_bib0118","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/s41467-020-15562-9","article-title":"Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV","volume":"11","author":"Ou","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.msard.2020.102174_bib0119","doi-asserted-by":"crossref","first-page":"580","DOI":"10.4049\/jimmunol.1400118","article-title":"Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients","volume":"193","author":"Palanichamy","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.msard.2020.102174_bib0120","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1007\/s00415-017-8594-9","article-title":"The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations","volume":"264","author":"Pardo","year":"2017","journal-title":"J Neurol."},{"key":"10.1016\/j.msard.2020.102174_bib0121","article-title":"Convalescent plasma to treat covid-19: Chinese strategy and experiences","author":"Pei","year":"2020","journal-title":"MedR\u03c7iv."},{"key":"10.1016\/j.msard.2020.102174_bib0122","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.msard.2018.09.009","article-title":"Herpes simplex virus encephalitis temporally associated with dimethyl fumarate-induced lymphopenia in a multiple sclerosis patient","volume":"26","author":"Perini","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2020.102174_bib0123","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl. J. Med."},{"key":"10.1016\/j.msard.2020.102174_bib0124","article-title":"critical illness pathophysiology driven by diffuse pulmonary thrombi and pulmonary endothelial dysfunction responsive to thrombolysis","author":"Poor","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.msard.2020.102174_bib0125","first-page":"1","article-title":"Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic","volume":"38","author":"Prompetchara","year":"2020","journal-title":"Asian Pac. J. Allergy Immunol."},{"issue":"10229","key":"10.1016\/j.msard.2020.102174_bib0126","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S0140-6736(20)30528-6","article-title":"Investigation of three clusters of COVID-19 in Singapore: implications for surveillance and response measures","volume":"395","author":"Pung","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2020.102174_bib0127","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.6775","article-title":"Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area","author":"Richardson","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.msard.2020.102174_bib0128","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2107","article-title":"Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: Comparison with SARS and MERS","author":"Rokni","year":"2020","journal-title":"Rev. Med. Virol."},{"issue":"Suppl 1","key":"10.1016\/j.msard.2020.102174_bib0129","first-page":"491","article-title":"Changes in lymphocyte subpopulations in highly active multiple sclerosis patients during cladribine treatment","volume":"26","author":"Ruggieri","year":"2019","journal-title":"Eur. J. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2020.102174_bib0130","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a029082","article-title":"Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Multiple Sclerosis","volume":"9","author":"Rush","year":"2019","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.msard.2020.102174_bib0131","doi-asserted-by":"crossref","first-page":"e1452","DOI":"10.1212\/WNL.0000000000008243","article-title":"Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing","volume":"93","author":"Ryerson","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102174_bib0132","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a032037","article-title":"B-Cell Therapies in Multiple Sclerosis","volume":"9","author":"Sabatino","year":"2019","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.msard.2020.102174_bib0133","doi-asserted-by":"crossref","first-page":"25800","DOI":"10.1073\/pnas.1915309116","article-title":"Anti-CD20 therapy depletes activated myelin-specific CD8+ T cells in multiple sclerosis","volume":"116","author":"Sabatino","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.msard.2020.102174_bib0134","doi-asserted-by":"crossref","first-page":"337","DOI":"10.55563\/clinexprheumatol\/xcdary","article-title":"COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?","volume":"38","author":"Sarzi-Puttini","year":"2020","journal-title":"Clin. Exp. Rheumatol."},{"issue":"S3","key":"10.1016\/j.msard.2020.102174_bib0135","first-page":"852","article-title":"Comparison of the B-cell recovery time following discontinuation of anti-CD20 therapies. EP1624","volume":"23","author":"Savelieva","year":"2017","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.msard.2020.102174_bib0136","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/intimm\/dxu096","article-title":"Therapeutic uses of anti-\u03b14-integrin (anti-VLA-4) antibodies in multiple sclerosis","volume":"27","author":"Schwab","year":"2015","journal-title":"Int. Immunol."},{"key":"10.1016\/j.msard.2020.102174_bib0137","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma","author":"Shen","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.msard.2020.102174_bib0138","doi-asserted-by":"crossref","DOI":"10.1126\/science.abb7015","article-title":"Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2","author":"Shi","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.msard.2020.102174_bib0139","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.101963","article-title":"Is antibody titer useful to verify the immunization after VZV Vaccine in MS patients treated with Fingolimod? A case series","volume":"40","author":"Signoriello","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2020.102174_bib0140","doi-asserted-by":"crossref","DOI":"10.1111\/pai.13263","article-title":"Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover","author":"Soresina","year":"2020","journal-title":"Pediatr. Allergy Immunol."},{"key":"10.1016\/j.msard.2020.102174_bib0141","first-page":"e13501","article-title":"COVID-19 and rationally layered social distancing","author":"Stein","year":"2020","journal-title":"Int. J. Clin. Pract."},{"issue":"15 Suppl","key":"10.1016\/j.msard.2020.102174_bib0142","article-title":"Effect of ocrelizumab on vaccine responses in pateinets with multiple sclerosis (S36.002)","volume":"90","author":"Stokmaier","year":"2018","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2020.102174_bib0143","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00281-008-0132-5","article-title":"Reconstitution of the immune system after hematopoietic stem cell transplantation in humans","volume":"30","author":"Storek","year":"2008","journal-title":"Semin Immunopathol."},{"issue":"7","key":"10.1016\/j.msard.2020.102174_bib0144","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s40263-015-0261-z","article-title":"Sphingosine 1-phosphate receptor modulators in multiple sclerosis","volume":"29","author":"Subei","year":"2015","journal-title":"CNS Drugs."},{"issue":"4","key":"10.1016\/j.msard.2020.102174_bib0145","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2217\/cer-2019-0169","article-title":"Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis","volume":"9","author":"Swallow","year":"2020","journal-title":"J. Comp. Eff. Res."},{"key":"10.1016\/j.msard.2020.102174_bib0146","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00415-018-8812-0","article-title":"Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation","volume":"265","author":"Tallantrye","year":"2018","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2020.102174_bib0147","doi-asserted-by":"crossref","DOI":"10.1038\/s41423-020-0400-4","article-title":"Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine","author":"Tai","year":"2020","journal-title":"Cell Mol. Immunol."},{"key":"10.1016\/j.msard.2020.102174_bib0148","first-page":"28","article-title":"Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer","author":"Tian","year":"2020","journal-title":"J. Thorac .Oncol."},{"issue":"1","key":"10.1016\/j.msard.2020.102174_bib0149","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1080\/22221751.2020.1729069","article-title":"Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody","volume":"9","author":"Tian","year":"2020","journal-title":"Emerg. Microbes Infect."},{"issue":"4","key":"10.1016\/j.msard.2020.102174_bib0150","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/s41591-020-0819-2","article-title":"Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19","volume":"26","author":"Thevarajan","year":"2020","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.msard.2020.102174_bib0151","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.1212\/NXI.0000000000000228","article-title":"Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS","volume":"3","author":"Thomas","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"1","key":"10.1016\/j.msard.2020.102174_bib0152","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12974-017-0817-6","article-title":"Fingolimod additionally acts as immunomodulator focused on the innate immune system beyond its prominent effects on lymphocyte recirculation","volume":"14","author":"Thomas","year":"2017","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.msard.2020.102174_bib0153","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1136\/jnnp-2014-307721","article-title":"Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy","volume":"86","author":"Tuohy","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"7","key":"10.1016\/j.msard.2020.102174_bib0154","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1179\/1743132812Y.0000000059","article-title":"Humoral immune response to influenza vaccine in natalizumab-treated MS patients","volume":"34","author":"V\u00e5gberg","year":"2012","journal-title":"Neurol. Res."},{"key":"10.1016\/j.msard.2020.102174_bib0155","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.94.15_supplement.5218","article-title":"Evaluation of risk factors in developing lymphopenia and hypogammaglobulinemia in anti-CD20 treated multiple sclerosis patients","author":"Vollmer","year":"2020","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2020.102174_bib0156","doi-asserted-by":"crossref","first-page":"e409","DOI":"10.1212\/NXI.0000000000000409","article-title":"Immune response to vaccines is maintained in patients treated with dimethyl fumarate","volume":"5","author":"von Hehn","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2020.102174_bib0157","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.msard.2020.102174_bib0158","article-title":"SARS-CoV-2 invades host cells via a novel route: CD147-spike protein","author":"Wang","year":"2020","journal-title":"BioR\u03c7iv"},{"key":"10.1016\/j.msard.2020.102174_bib0159","doi-asserted-by":"crossref","DOI":"10.1038\/s41423-020-0498-4","article-title":"SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion","author":"Wang","year":"2020","journal-title":"Cell. Mol. Immunol."},{"issue":"11","key":"10.1016\/j.msard.2020.102174_bib0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002685","article-title":"Lymphopenia and risk of infection and infection-related death in 98,344 individuals from a prospective Danish population-based study","volume":"15","author":"Warny","year":"2018","journal-title":"PLoS Med"},{"issue":"10229","key":"10.1016\/j.msard.2020.102174_bib0161","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/S0140-6736(20)30633-4","article-title":"Clinical course andmortality risk of severe COVID-19","volume":"395","author":"Weiss","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2020.102174_bib0162","doi-asserted-by":"crossref","unstructured":"Wen W, Su W, Tang H, et\u00a0al. immune cell profiling of covid-19 patients in the recovery stage by single-cell sequencing. medRxiv. doi: 10.1101\/2020.03.23.20039362.","DOI":"10.1101\/2020.03.23.20039362"},{"key":"10.1016\/j.msard.2020.102174_bib0163","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-020-09822-3","article-title":"Multiple sclerosis and the risk of infection: considerations in the threat of the novel coronavirus, COVID-19\/SARS-CoV-2","author":"Willis","year":"2020","journal-title":"J Neurol."},{"key":"10.1016\/j.msard.2020.102174_bib0164","article-title":"A single cell atlas of the peripheral immune response to severe COVID-10","author":"Wilk","year":"2020","journal-title":"MedR\u03c7iv"},{"key":"10.1016\/j.msard.2020.102174_bib0165","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1136\/jnnp-2017-317493","article-title":"Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study","volume":"89","author":"Wijnands","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"key":"10.1016\/j.msard.2020.102174_bib0166","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1177\/1352458518796675","article-title":"Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study","volume":"25","author":"Wray","year":"2019","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2020.102174_bib0167","article-title":"Antibody Detection and Dynamic Characteristics in Patients with COVID-19","author":"Xiang","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.msard.2020.102174_bib0168","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/s41591-020-0817-4","article-title":"Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding","volume":"26","author":"Xu","year":"2020","journal-title":"Gong S. Nat .Med."},{"key":"10.1016\/j.msard.2020.102174_bib0169","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2020","journal-title":"Lancet Respir. Med."},{"issue":"11","key":"10.1016\/j.msard.2020.102174_bib0171","doi-asserted-by":"crossref","first-page":"5642e5650","DOI":"10.1128\/JVI.78.11.5642-5650.2004","article-title":"pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN","volume":"78","author":"Yang","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.msard.2020.102174_bib0172","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1042\/BJ20050698","article-title":"Bcl-xL inhibits T-cell apoptosis induced by expression of SARS coronavirus E protein in the absence of growth factors","volume":"392","author":"Yang","year":"2005","journal-title":"Biochem. J."},{"issue":"0","key":"10.1016\/j.msard.2020.102174_bib0170","first-page":"E009","article-title":"A pathological report of three COVID-19 cases by minimally invasive autopsies","volume":"49","author":"Yao","year":"2020","journal-title":"W. Zhonghua Bing Li Xue Za Zhi."},{"key":"10.1016\/j.msard.2020.102174_bib0176","article-title":"Patient-derived mutations impact pathogenicity of SARS-CoV2","author":"Yao","year":"2020","journal-title":"medR\u03c7iv"},{"key":"10.1016\/j.msard.2020.102174_bib0173","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2020.03.001","article-title":"Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation","author":"Ye","year":"2020","journal-title":"J. Infect."},{"key":"10.1016\/j.msard.2020.102174_bib0174","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/356063a0","article-title":"Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin","volume":"356","author":"Yednock","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.msard.2020.102174_bib0175","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1128\/JVI.80.6.2684-2693.2006","article-title":"Modelling the early events of severe acute respiratory syndrome coronavirus infection in vitro","volume":"80","author":"Yen","year":"2006","journal-title":"BA. J. Virol."},{"key":"10.1016\/j.msard.2020.102174_bib0177","doi-asserted-by":"crossref","DOI":"10.7326\/L20-0227","article-title":"Inflammatory response cells during acute respiratory distress syndrome in patients with coronavirus disease 2019 (COVID-19)","author":"Zhang","year":"2020","journal-title":"Ann. Intern Med."},{"issue":"0","key":"10.1016\/j.msard.2020.102174_bib0178","article-title":"Comparison of clinical and pathological features between severe acute respiratory syndrome and coronavirus disease 2019]","volume":"43","author":"Zhang","year":"2020","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi."},{"key":"10.1016\/j.msard.2020.102174_bib0179","first-page":"2020","article-title":"Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019","author":"Zhao","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.msard.2020.102174_bib0180","article-title":"Functional exhaustion of antiviral lymphocytes in COVID-19 patients","author":"Zheng","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.msard.2020.102174_bib0181","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.msard.2020.102174_bib0182","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.25884","article-title":"Clinical characteristics of 3,062 COVID-19 patients: a meta-analysis","author":"Zhu","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.msard.2020.102174_bib0183","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"China Novel Coronavirus investigating and research team. a novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl. J. Med."},{"key":"10.1016\/j.msard.2020.102174_bib0184","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419878340","article-title":"Reduced serum immunoglobulin G concentrations in multiple sclerosis: prevalence and association with disease-modifying therapy and disease course","volume":"12","author":"Zoehner","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820302509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820302509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:51:19Z","timestamp":1761900679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034820302509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":184,"alternative-id":["S2211034820302509"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102174","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102174","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102174"}}